Cite
LBA4 The efficacy and safety of TQ-B2450 alone/with anlotinib in previously treated advanced non-small cell lung cancer (NSCLC): A multicenter, randomized, double-blind, placebo-controlled clinical trial.
MLA
Han, B., et al. “LBA4 The Efficacy and Safety of TQ-B2450 Alone/with Anlotinib in Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC): A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial.” Annals of Oncology, vol. 32, Dec. 2021, p. S1429. EBSCOhost, https://doi.org/10.1016/j.annonc.2021.10.219.
APA
Han, B., Li, K., Wang, Q., Cheng, Y., Yang, L., & Li, Y. (2021). LBA4 The efficacy and safety of TQ-B2450 alone/with anlotinib in previously treated advanced non-small cell lung cancer (NSCLC): A multicenter, randomized, double-blind, placebo-controlled clinical trial. Annals of Oncology, 32, S1429. https://doi.org/10.1016/j.annonc.2021.10.219
Chicago
Han, B., K. Li, Q. Wang, Y. Cheng, L. Yang, and Y. Li. 2021. “LBA4 The Efficacy and Safety of TQ-B2450 Alone/with Anlotinib in Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC): A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial.” Annals of Oncology 32 (December): S1429. doi:10.1016/j.annonc.2021.10.219.